Final answer:
Patients with Chromosome 22q11.2 Deletion Syndrome are prone to infections due to immune system impairment. Treatment involves antibiotics, antiviral medications, immunoglobulin replacement therapy, and prevention through vaccinations and hygiene practices. A multi-disciplinary approach is also important for managing other aspects of the syndrome.
Step-by-step explanation:
Chromosome 22q11.2 Deletion Syndrome and Infections
Patients with Chromosome 22q11.2 Deletion Syndrome, also known as DiGeorge Syndrome or Velocardiofacial Syndrome, are prone to various infections due to their impaired immune system. This condition often leads to physical and mental abnormalities due to the deletion of a segment of chromosome 22. One of the key issues is a poorly functioning thymus, which can result in a compromised immune system.
These individuals are particularly susceptible to respiratory and ear infections, as well as infections caused by atypical bacteria or viruses. The treatment of infections in these patients typically involves prompt use of antibiotics or antiviral medications, as well as immunoglobulin replacement therapy if there is a significant immune deficiency. Prevention of infections through good hygiene practices and staying up to date with vaccinations is also crucial.
In addition to treating the infections, ongoing management from a team of specialists is essential to address the various aspects of the syndrome, including cardiac, developmental, speech, and feeding issues, among others.